Skip to main content
. 2020 Dec 15;2(5):747–754. doi: 10.1016/j.jaccao.2020.09.008

Table 2.

Clinical Variables According to Anticoagulation Status in Patients With CHA2DS2-VASc Scores ≥2 and HAS-BLED Scores <3: Full Cohort (N = 296)

Total (N = 296) No AC (n = 131) AC (n = 165) p Value
Age (yrs) 74.9 ± 8.3 73.8 ± 8.8 76.2 ± 7.6 0.003
Female 123 (41.6) 64 (48.9) 59 (35.8) 0.020
Hypertension 194 (65.5) 74 (56.5) 120 (72.7) 0.004
Heart failure 25 (8.4) 7 (5.3) 18 (10.9) 0.091
Prior atrial fibrillation 143 (48.3) 39 (29.8) 104 (63.0) <0.001
Diabetes 81 (27.4) 34 (26.0) 47 (28.5) 0.634
Prior stroke 29 (9.8) 10 (7.6) 19 (11.5) 0.265
Vascular disease 61 (20.6) 25 (19.1) 36 (21.8) 0.564
Renal disease 8 (2.7) 5 (3.8) 3 (1.8) 0.293
Liver disease 3 (1.0) 2 (1.5) 1 (0.6) 0.433
Prior major bleed 27 (9.1) 26 (19.8) 1 (0.6) <0.001
Labile INR 3 (1.0) 2 (1.5) 1 (0.6) 0.476
VTE 21 (7.1) 7 (5.3) 14 (8.5) 0.404
Chemotherapy, current use 142 (48.0) 77 (58.8) 65 (39.4) <0.001
Chemotherapy, noncurrent, prior 3 months 36 (12.2) 18 (13.7) 18 (10.9) 0.592
Perioperative atrial fibrillation 81 (27.4) 47 (35.9) 34 (20.6) 0.006
NSAID 34 (11.5) 20 (15.3) 14 (8.5) 0.108
Ibrutinib 2 (0.7) 2 (1.5) 0 (0) 0.383
Platelet count <50,000/μl 26 (8.8) 24 (18.3) 2 (1.2) <0.001
Karnofsky score 80 (70–90) 80 (70–90) 90 (70–90) 0.682
LVEF (%) 60 (58–63) 63 (58–63) 58 (58–63) 0.512
Brain metastases 5 (1.7) 4 (3.1) 1 (0.6) 0.246
Cancer type
 Heme 65 (22.0) 45 (34.4) 20 (12.1) <0.001
 GI 49 (16.6) 20 (15.3) 29 (17.6) 0.688
 Cutaneous 41 (13.9) 8 (6.1) 33 (20.0) <0.001
 GU 41 (13.9) 15 (11.5) 26 (15.8) 0.357
 Lung 40 (13.5) 19 (14.5) 21 (12.7) 0.805
 Breast 16 (5.4) 8 (6.1) 8 (4.8) 0.841
 GYN 10 (3.4) 4 (3.1) 6 (3.6) 0.783
 Sarcoma 10 (3.4) 3 (2.3) 7 (4.2) 0.541
 Other 25 (8.4) 10 (7.6) 15 (9.1) 0.797

Values are mean ± SD, n (%), or median (interquartile range).

Abbreviations as in Table 1.